Past 10 year's financial track record analysis by Moneyworks4me indicates that Prolife Industries Ltd is a good quality company.
The key valuation ratios of Prolife Industries Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Prolife Industries Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 13.5% | 14.3% | 16.7% | 20.2% | 21.9% | 29.4% | 31.3% | 22.6% | 29.9% | 30.8% | - |
| Value Creation Index ⓘ | 0.0 | 0.0 | 0.2 | 0.5 | 0.6 | 1.1 | 1.2 | 0.6 | 1.1 | 1.2 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 19.6 | 22.3 | 27.2 | 27.3 | 29.7 | 50.5 | 73.3 | 73.2 | 78.3 | 56.8 | 57 |
| Sales YoY Gr. | - | 13.8% | 21.9% | 0.4% | 8.7% | 70% | 45.4% | -0.2% | 7% | -27.4% | - |
| Adj EPS ⓘ | 1.8 | 1.5 | 2.3 | 3.3 | 4.3 | 8.7 | 13.1 | 9.3 | 14.4 | 20.7 | 21.4 |
| YoY Gr. | - | -14.5% | 47.1% | 46.2% | 30.4% | 103.5% | 50.1% | -29.1% | 54.7% | 44.1% | - |
| BVPS (₹) ⓘ | 20.8 | 24.1 | 21.2 | 24.6 | 29.6 | 39.1 | 52.3 | 62.5 | 79 | 100.1 | 100.1 |
| Adj Net Profit ⓘ | 0.3 | 0.2 | 0.9 | 1.4 | 1.8 | 3.6 | 5.4 | 3.8 | 5.9 | 8.5 | 9 |
| Cash Flow from Ops. ⓘ | 3 | 4.2 | -0.1 | 5.8 | 0.8 | 10 | 5.1 | 3.7 | 0.1 | 17.3 | - |
| Debt/CF from Ops. ⓘ | 3.4 | 2.1 | -65 | 0.8 | 8.8 | 0.8 | 1.1 | 1.3 | 34.9 | 0.2 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 12.6% | 13.9% | -8.2% | -27.4% | ||||
| Adj EPS ⓘ | 31.3% | 37% | 16.5% | 44.1% | ||||
| BVPSⓘ | 19.1% | 27.6% | 24.2% | 26.7% | ||||
| Share Price | - | 59.7% | 33.8% | 17.1% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 9.3 | 6.8 | 15 | 14.4 | 15.8 | 25.4 | 28.7 | 16.2 | 20.3 | 23.1 | 21.4 |
| Op. Profit Mgn % ⓘ | 9.9 | 8.1 | 9.6 | 12.9 | 14.2 | 11 | 11.2 | 8.2 | 11.2 | 20.8 | NAN |
| Net Profit Mgn % ⓘ | 1.4 | 1 | 3.4 | 4.9 | 5.9 | 7.1 | 7.3 | 5.2 | 7.5 | 14.9 | 15.4 |
| Debt to Equity ⓘ | 3.3 | 2.4 | 0.6 | 0.5 | 0.6 | 0.5 | 0.3 | 0.2 | 0.1 | 0.1 | - |
| Working Cap Days ⓘ | 207 | 169 | 115 | 113 | 139 | 130 | 147 | 196 | 159 | 144 | 0 |
| Cash Conv. Cycle ⓘ | 107 | 74 | 38 | 16 | 19 | 27 | 16 | 21 | 32 | 59 | 0 |
Return on Equity has increased versus last 3 years average to 21.40%
Net Profit is growing at healthy rate in last 3 years 16.48%
Sales growth has been subdued in last 3 years -8.16%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 21.4 | - |
| TTM Sales (₹ Cr.) | 56.8 | - |
| BVPS (₹.) ⓘ | 100.1 | - |
| Reserves (₹ Cr.) ⓘ | 37 | - |
| P/BV ⓘ | 2.78 | - |
| PE ⓘ | 13.01 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 114 |
| Equity (₹ Cr.) | 4.1 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 55.9 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20 | 22 | 27 | 27 | 30 | 50 | 73 | 73 | 78 | 57 |
| Operating Expenses ⓘ | 18 | 21 | 25 | 24 | 25 | 45 | 65 | 67 | 70 | 45 |
| Manufacturing Costs | 3 | 1 | 2 | 3 | 3 | 3 | 5 | 7 | 8 | 6 |
| Material Costs | 13 | 17 | 21 | 19 | 19 | 38 | 55 | 54 | 54 | 32 |
| Employee Cost | 0 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 3 |
| Other Costs ⓘ | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 3 | 4 | 3 |
| Operating Profit ⓘ | 2 | 2 | 3 | 4 | 4 | 6 | 8 | 6 | 9 | 12 |
| Operating Profit Margin (%) | 9.4% | 8.0% | 9.3% | 12.8% | 14.2% | 11.0% | 11.2% | 8.2% | 11.1% | 20.8% |
| Other Income ⓘ | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 2 | 2 | 2 |
| Interest ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Depreciation ⓘ | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 1 | 1 | 1 | 2 | 3 | 6 | 7 | 6 | 9 | 12 |
| Tax ⓘ | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 3 |
| Profit After Tax | 0 | 1 | 1 | 2 | 2 | 4 | 5 | 4 | 7 | 9 |
| PAT Margin (%) | 1.9% | 2.4% | 3.2% | 5.5% | 6.9% | 8.0% | 7.5% | 5.9% | 8.8% | 15.4% |
| Adjusted EPS (₹) | 1.3 | 1.8 | 2.1 | 3.7 | 5.0 | 9.9 | 13.4 | 10.5 | 16.9 | 21.4 |
| Dividend Payout Ratio (%) | 8% | 6% | 9% | 7% | 6% | 3% | 2% | 3% | 2% | 2% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 3 | 4 | 9 | 10 | 12 | 16 | 21 | 26 | 32 | 41 |
| Share Capital ⓘ | 1 | 1 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves ⓘ | 2 | 2 | 5 | 6 | 8 | 12 | 17 | 21 | 28 | 37 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 10 | 9 | 5 | 5 | 7 | 8 | 5 | 5 | 2 | 4 |
| Long Term Debt | 9 | 7 | 7 | 6 | 8 | 5 | 5 | 5 | 4 | 4 |
| Short Term Debt | 1 | 2 | -2 | -1 | -1 | 2 | 1 | 0 | -2 | 0 |
| Trade Payables | 3 | 3 | 4 | 5 | 6 | 9 | 19 | 22 | 4 | 3 |
| Others Liabilities ⓘ | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 |
| Total Liabilities ⓘ | 18 | 16 | 18 | 21 | 27 | 36 | 49 | 55 | 41 | 52 |
Fixed Assets | ||||||||||
| Gross Block | 5 | 4 | 7 | 9 | 11 | 11 | 12 | 15 | 16 | 17 |
| Accumulated Depreciation | 2 | 1 | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9 |
| Net Fixed Assetsⓘ | 3 | 3 | 6 | 7 | 8 | 7 | 7 | 9 | 9 | 9 |
| CWIP ⓘ | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investmentsⓘ | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Inventories | 6 | 3 | 2 | 3 | 2 | 6 | 8 | 11 | 6 | 6 |
| Trade Receivables | 3 | 4 | 4 | 3 | 8 | 7 | 16 | 17 | 11 | 5 |
Cash Equivalents  ⓘ
| 0 | 0 | 0 | 1 | 1 | 3 | 1 | 1 | 1 | 22 |
| Others Assetsⓘ | 2 | 2 | 1 | 3 | 4 | 8 | 13 | 13 | 11 | 7 |
| Total Assets ⓘ | 18 | 16 | 18 | 21 | 27 | 36 | 49 | 55 | 41 | 52 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 3 | 4 | 0 | 6 | 1 | 10 | 5 | 4 | 0 | 17 |
| PBT ⓘ | 0 | 1 | 1 | 2 | 3 | 6 | 7 | 6 | 9 | 12 |
| Adjustment ⓘ | 2 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 1 |
| Changes in Working Capital ⓘ | 1 | 2 | -2 | 3 | -3 | 4 | -2 | -2 | -8 | 8 |
| Tax Paid ⓘ | 0 | 0 | -1 | -1 | -1 | -2 | -2 | -2 | -2 | -3 |
| Cash Flow From Investing Activity ⓘ | -1 | -1 | -3 | -3 | -2 | -5 | -6 | -3 | 1 | 3 |
| Capex | -1 | -1 | -3 | -2 | -1 | -1 | -1 | -3 | -1 | -1 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | -1 | -1 | -1 | -5 | -5 | 0 | 3 | 5 |
| Cash Flow From Financing Activityⓘ | -2 | -3 | 3 | -2 | 2 | -4 | -1 | 0 | -1 | -1 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -1 | -2 | 0 | -1 | 3 | -3 | -1 | 0 | -1 | 0 |
| Interest Paid ⓘ | -1 | -1 | -1 | -1 | -1 | -1 | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow ⓘ | 0 | 0 | 0 | 1 | 0 | 2 | -2 | 1 | 0 | 20 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 12.95 | 15.7 | 14.25 | 16.03 | 18.33 | 28.7 | 29.4 | 18.32 | 23.87 | 23.88 |
| ROCE (%) | 13.54 | 14.32 | 16.66 | 20.24 | 21.87 | 29.37 | 31.27 | 22.56 | 29.93 | 30.82 |
| Asset Turnover Ratio | 1.16 | 1.32 | 1.57 | 1.38 | 1.24 | 1.62 | 1.75 | 1.41 | 1.62 | 1.22 |
| PAT to CFO Conversion(x) | N/A | 4 | 0 | 3 | 0.5 | 2.5 | 1 | 1 | 0 | 1.89 | Working Capital Days |
| Receivable Days | 57 | 59 | 55 | 48 | 68 | 55 | 57 | 81 | 64 | 51 |
| Inventory Days | 116 | 78 | 38 | 39 | 33 | 31 | 36 | 48 | 40 | 37 |
| Payable Days | 86 | 70 | 64 | 91 | 104 | 72 | 93 | 138 | 89 | 41 |
The company was incorporated as Mamta Dyes and Intermediaries Private Limited under the provision of the Companies Act, 1956 vide certificate of incorporation dated July 27, 1994 issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Consequent upon the conversion of the company to public limited company, the name of the company was changed to Mamta Dyes and Intermediaries Limited and fresh certificate of incorporation dated February 20, 1997 was issued by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, the name of the company was changed to R R J-Dyes and Intermediates Limited vide fresh certificate of incorporation dated February 20, 1997 was issued by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Later on the name of the company was changed to Prolife Industries Limited and fresh certificate of Incorporation dated March 7, 2013 pursuant to change of name was issued by Registrar of Companies, Gujarat, Dadra and Nagar Haveli.
The company originally founded in the year 1994 in the name of Mamta Dyes & Intermediates Private Ltd and has been in this Industry from the very inception. Company has established even its own Research & Development Department within few years of incorporation of the company. It has already succeeded in developing very high quality Specialty Chemicals as result of thorough knowledge and R & D efforts of the Chairman and Managing Director of the company who has sound knowledge as well as vast experience of two decades in the chemical industry. The company has established its presence in domestic as well export market and are regularly catering to the needs of their customers in many countries including U.S.A, Spain, Switzerland, Germany, France, Taiwan, Japan, Germany, Brazil etc.
At present, the company is mainly manufacturing ranges of intermediaries for dyes, pigments, pharmaceuticals agro chemicals. The company’s existing and proposed product and products mix are Dehydro Thio Para Toluidine Sulfonic Acid (DTPTSA), Amino Phenoxy Propane Sulfonic Acid (SPA), Amino Methyl Phenoxy Sulfonic Acid (SPMT), PYBIZS- 4-Nitrile-1-Hydroxy-8-Metoxy-3-Methyl Benzo [4,5] Imidazo [1,2A] Pyridine-7 & Sulphonic Acid & its sodium salt, Basic Red51/Red 76/Brown16/Brown17/Brown99/yellow-1/Yellow57/Orange31, 2-Chloro Methyl -3,4- Dimethoxy Pyridine, Octahydro-4B-Methyl-9 (Methylamino), Di Amino Bisphenoxy Ethane, 5-Methoxy 6- Amino Benz Imidazole Para Nitro Aniline, Epsilon Acid, 2:4 Di Nitro Aniline, Dichloro Para Nitro Aniline, Ortho Chloro Para Nitro Aniline, 6 Chloro 2:4 Di Nitro Aniline, 6 Bromo Di Nitro Aniline.
Business area of the company
The company is engaged in the business of manufacturing special and exclusive range of intermediates for dyes, pigments, pharmaceuticals, agrochemicals and others.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
